Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2/18/26 21:38 | 2/18/26 | SLDB | Health | BioPrd | Biological Products, (No Diag | Cumbo Alexander | MA | DO | P,CEO | 3 | S.d | -929 | 6.37 | 0 | -146 | 271 | D | |||||||||||||||
2/18/26 21:34 | 2/18/26 | SLDB | Health | BioPrd | Biological Products, (No Diag | Hanrahan Jessie | MA | O | Chief Re | 3 | S.d | -274 | 6.38 | 0 | -43 | 83 | D | |||||||||||||||
2/18/26 21:32 | 2/18/26 | SLDB | Health | BioPrd | Biological Products, (No Diag | Ganot Ilan | MA | D | 4 | S.d | -69 | 6.20 | 0 | -11 | 146 | I | ||||||||||||||||
2/18/26 21:31 | 2/18/26 | SLDB | Health | BioPrd | Biological Products, (No Diag | Herzich Paul | MA | O | CTO | 3 | S.d | -260 | 6.38 | 0 | -41 | 80 | D | |||||||||||||||
2/18/26 21:31 | 2/18/26 | SLDB | Health | BioPrd | Biological Products, (No Diag | Howton David T | MA | O | COO | 3 | S.d | -408 | 6.37 | 0 | -64 | 117 | D | |||||||||||||||
2/18/26 21:28 | 2/18/26 | SLDB | Health | BioPrd | Biological Products, (No Diag | Brooks Gabriel | MA | O | Chief Me | 3 | S.d | -264 | 6.44 | 0 | -41 | 97 | D | |||||||||||||||
2/18/26 21:25 | 2/18/26 | SLDB | Health | BioPrd | Biological Products, (No Diag | Tan Kevin | MA | O | CFO,Trea | 4 | S.d | -330 | 6.25 | 0 | -53 | 109 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |